Home Print this page Email this page
Users Online: 10
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 

    Article Cited by others


A case study of Gavi'S human papillomavirus vaccine support programme

Castro Aimee, Cinà Margherita, Helmer-Smith Mary, Vlček Christian, Oghor Collins, Cazabon Danielle

Year : 2017| Volume: 5| Issue : 1 | Page no: 2-7

   This article has been cited by
1 The patent buyout price for human papilloma virus (HPV) vaccine and the ratio of R&D costs to the patent value
Mario Songane,Volker Grossmann,Magdalena Grce
PLOS ONE. 2021; 16(1): e0244722
[Pubmed]  [Google Scholar] [DOI]
2 Global health systems partnerships: a mixed methods analysis of Mozambique’s HPV vaccine delivery network actors
Caroline Soi,Jessica Shearer,Baltazar Chilundo,Vasco Muchanga,Luisa Matsinhe,Sarah Gimbel,Kenneth Sherr
BMC Public Health. 2020; 20(1)
[Pubmed]  [Google Scholar] [DOI]
3 Implementation strategy and cost of Mozambique’s HPV vaccine demonstration project
Caroline Soi,Joseph B. Babigumira,Baltazar Chilundo,Vasco Muchanga,Luisa Matsinhe,Sarah Gimbel,Orvalho Augusto,Kenneth Sherr
BMC Public Health. 2019; 19(1)
[Pubmed]  [Google Scholar] [DOI]
4 Global human papilloma virus vaccine implementation: An update
Sasidharanpillai Sabeena,Parvati V. Bhat,Veena Kamath,Govindakarnavar Arunkumar
Journal of Obstetrics and Gynaecology Research. 2018;
[Pubmed]  [Google Scholar] [DOI]


Read this article